PBAC's latest decision on Eflornithine: Recommended with restriction (2025). Considered for Post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after prior multiagent, multimodality therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients aged 1 year and older with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy and are in remission either at the end of upfront therapy or after any previous relapse or refractory therapy.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
EFS, OS
Key trials
NMTRC003b
Comparator
standard of care (SOC)
Economic model
CEA
ICER note
ICER value not stated in the public text; document indicates cost-effectiveness analysis was performed but specific ICER range not disclosed.